Cover background

In the News

November 11, 2025

Mark Cuban sends strong message on major Medicare change

See More

August 8, 2025

Currax’s human-centric campaign sets an example for marketing weight loss drugs

See More

July 14, 2025

Need a DTC platform? Here’s how one company built its own. Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.

See More

June 9, 2025

Currax CEO George Hampton Featured on Bloomberg Markets: Navigating Innovation and Access in Pharma

See More

April 15, 2025

Currax CEO on pharmacuetical tariffs, stockpiling and foreign production

See More

April 7, 2025

FierceMadness: AstraZeneca battles itself in Final Four of 2025 Drug Ad Tournament—VOTE NOW

See More

March 20, 2025

Currax gets FDA approval for second manufacturing site for oral weight loss drug

See More

March 14, 2025

High Price of GLP-1 Agents Tip Cost-Benefit Scale Unfavorably

See More

February 7, 2025

Considerations for Prescribing GLP-1s Get More Complicated

See More

January 10, 2025

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

See More

December 4, 2024

Watch the CONTRAVE® (naltrexone HCl/bupropion HCl) TV commercial w/ the track Don't Own Me.

See More

November 10, 2024

Why weight-loss drugs aren't covered by insurance

See More

October 30, 2024

Currax is benefitting from weight loss drug demand, says CEO George Hampton

See More

September 24, 2024

Currax, maker of weight loss drug Contrave, constructs campaign to educate on "food noise"

See More

August 26, 2024

Currax Sees Demand for Weight-Loss Drug Contrave Growing

See More

July 23, 2024

New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues

See More

May 23, 2024

Weight-loss drugs: How low costs, easy access change the game now

See More

April 24, 2024

Currax Pharmaceuticals CEO says the GLP-1 conversation isn’t one-size-fits-all

See More

March 29, 2024

Contrave mimics diet and exercise: George Hampton

See More

March 1, 2024

The obesity population in the U.S. is 95% untreated, says Currax CEO George Hampton

See More

January 29, 2024

Currax Pharmaceuticals CEO on North Carolina ending obesity drug coverage

See More

March 6, 2022

The Boss: If you were a toddler soccer champion, George Hampton wants to know

See More